SkinBioTherapeutics (GB:SBTX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SkinBioTherapeutics plc has achieved remarkable growth through strategic acquisitions and expanding its product lineup, resulting in a projected turnover of £6.3 million for FY25. The company has successfully extended its Croda partnership and launched new products in Europe, bolstering its presence in the skin health market. With these developments, SkinBioTherapeutics anticipates becoming cash flow positive by FY25, minimizing the need for further fundraising.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.